• No results found

Differentiated thyroid carcinoma : nuclear medicine studies Verkooijen, R.B.T.

N/A
N/A
Protected

Academic year: 2021

Share "Differentiated thyroid carcinoma : nuclear medicine studies Verkooijen, R.B.T."

Copied!
7
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Differentiated thyroid carcinoma : nuclear medicine studies

Verkooijen, R.B.T.

Citation

Verkooijen, R. B. T. (2009, September 15). Differentiated thyroid carcinoma : nuclear medicine studies. Retrieved from https://hdl.handle.net/1887/13978

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/13978

Note: To cite this publication please use the final published version (if applicable).

(2)

Differentiated Thyroid Carcinoma Nuclear Medicine Studies

R.B.T. Verkooijen

(3)

Differentiated Thyroid Carcinoma; Nuclear Medicine Studies Copyright: R.B.T. Verkooijen

Eindhoven 2009

ISBN 978-90-8759-076-5

Cover design: BVD Buro voor design, ’s-Gravenhage Printed by: U2pi B.V. (jouwboek.nl), Voorburg

© 2009 R.B.T. Verkooijen

The printing of this thesis was financially supported by:

- GE Healthcare, Eindhoven - Genzyme Nederland, Naarden

- IBA molecular, Louvain-la-Neuve, België - Covidien Nederland B.V., Zaltbommel

Copyright of individual chapters lies with the publisher of the journal listed at the beginning of each respective chapter. No part of this thesis may be reproduced in any form, by print, photocopy, digital file, internet, or any other means without written permission from the author.

ii

(4)

Differentiated Thyroid Carcinoma Nuclear Medicine Studies

Proefschrift

ter verkrijging van

de graad van Doctor aan de Universiteit Leiden,

op gezag van Rector Magnificus prof. mr. P.F. van der Heijden, volgens besluit van het College voor Promoties

te verdedigen op dinsdag 15 september 2009 klokke 13.45 uur

door

Ronald B.T. Verkooijen

geboren te ’s-Gravenhage in 1972

(5)

iv

Promotiecommissie

Promotores:

Prof. dr. J.A. Romijn Prof. dr. J.W.A. Smit

Co-promotor:

Dr. M.P.M. Stokkel

Overige leden:

Prof. dr. B.L.F. van Eck-Smit (referent) Prof. dr. J. Kievit

Dr. E.P.M. van der Kleij-Corssmit Prof. dr. J. Morreau

Prof. dr. P.P. van Rijk Prof. dr. G.J.J. Teule

(6)

Contents

Chapter 1 General introduction and aims of this thesis 7

Chapter 2 Radioiodine-131 in differentiated thyroid cancer: 29 a retrospective analysis of an uptake-related ablation

strategy

Chapter 3 The success rate of 131I ablation in differentiated thyroid 51 cancer: comparison of uptake-related and fixed-dose

strategies

Chapter 4 The success rate of 131I ablation in thyroid cancer patients is 71 significantly reduced after a diagnostic activity of

40 MBq 131I

Chapter 5 A new functional parameter measured at the time of 89 ablation that can be used to predict differentiated thyroid

cancer recurrence during follow-up

Chapter 6 The incidence of second primary tumors in thyroid cancer 109 patients is increased, but not related to treatment of thyroid

cancer

Chapter 7 Indium-111 octreotide scintigraphy for the detection of 127 non-functioning metastases from differentiated thyroid

cancer: diagnostic and prognostic value

Chapter 8 Six month follow-up after 111In-DTPA-octreotide therapy 149 in patients with progressive radioiodine non-responsive

thyroid cancer

Chapter 9 Summary and Discussion 175

Chapter 10 Samenvatting 191

Nawoord 203

List of Publications 205

Curriculum Vitae 207

(7)

Referenties

GERELATEERDE DOCUMENTEN

The aim of the study described in chapter 8 was to determine the effect of 111 In- DTPA-octreotide therapy in patients with progressive radioiodine non- responsive thyroid cancer

There are several reasons for routine ablation after surgery [24]: (a) to enable detection of a carcinoma recurrence by RaI scanning; (b) RaI can destroy microscopic foci of

As we defined unsuccessful ablation as the presence of radioiodine uptake in the neck region, we did not distinguish between residual normal thyroid tissue in the thyroid

All DTC patients with M0 disease who had undergone (near-) total thyroidectomy followed by 131 I ablation were included. Tumor staging was scored according to the criteria of

Consequently, in order to maximize the success rate of 131 I ablation and minimize the number of required additional 131 I therapies, 24-h uptake measurements or

Although tumor stage, age, and standard biochemical values significantly differ between patients with and without recurrent disease or between patients with M0 and M1 tumor stage,

As 13-cis retinoic acid has a lower affi nity for RAR than other retinoids (14) and the retinoid receptor RXR may also be important in thyroid carcinoma (15,16), we performed

Triiodothyronine suppresses in vitro iodide uptake and expression of NIS The introduction of rhTSH for the diagnosis, initial therapy (ablation) and under certain circumstances